KIROMIC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kiromic BioPharma, Inc. and Encourages Investors to Contact the Firm

Investors have until October 4, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, August 10, 2022
Information
Tags: 
Class Action Lawsuit, Professional Services, Legal, FDA, P.C, Telephone, IND, Kirom Bukhoroi, Prospectus, Court, Company, Complaint, Register, NASDAQ, Immunotherapy, Jeanne Eagels, Offering, IPO, Person, Pharmaceutical industry
Geotags: 
UNITED STATES, NORTH AMERICA, NEW YORK, CALIFORNIA, SOUTH CAROLINA
⚠ generated by AI ↴
Organisation: 
BRAGAR EAGEL & SQUIRE, P.C.
Stock Symbol: 
NASDAQ:KRBP
Summary
Key Points: 
  • Investors have until October 4, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • The Offering Documents failed to disclose this information, instead representing that clinical testing was expected to proceed in the third quarter of 2021.
  • Clinical testing did not proceed in the third quarter of 2021, nor was it likely given the FDAs imposition of a clinical hold.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.


Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Kiromic BioPharma, Inc. (“Kiromic” or the “Company”) (NASDAQ: KRBP) in the United States district Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Kiromic securities between June 25, 2021 and August 13, 2021, both dates inclusive, or pursuant to the Company’s July 2, 2021 IPO (the “Class Period”). Investors have until October 4, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

The Complaint alleges that the Offering Documents failed to disclose that the FDA had, prior to the filing of the Registration Statement and Prospectus, imposed a clinical hold, and in fact, contained statements indicating that it had not. Given that the Offering closed on July 2, 2021, more than thirty (30) days after the Company submitted the IND applications for its two immunotherapy product candidates, investors were assured that no clinical hold had been issued and clinical trials would commence. The Company, however, had received communications from the FDA on June 16 and 17, 2021, informing it that the FDA was placing the IND applications for its two candidate products on clinical hold. The Offering Documents failed to disclose this information, instead representing that clinical testing was expected to proceed in the third quarter of 2021. Clinical testing did not proceed in the third quarter of 2021, nor was it likely given the FDA’s imposition of a clinical hold.

If you purchased or otherwise acquired Kiromic shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright: 
Copyright Business Wire 2022